×
About 441,634 results

Immunotherapy and Beyond: Treatment Options and Potential Markers in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200227/full/

Jul 2nd, 2020 - Head and neck cancers account for approximately 4% of all cancers in the United States1 and are the eighth most common cancer affecting men in the United States.2 The diagnosis of recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) carries a poor prognosis, with an overall survival (OS) of approximately 1 year.

Transoral Resection Followed by Low-Dose Radiation for Some Oropharyngeal Cancers
https://ascopost.com/news/may-2020/transoral-resection-followed-by-low-dose-radiation-for-some-oropharyngeal-cancers/

May 29th, 2020 - The final results of the randomized phase II ECOG-ACRIN E3311 trial were presented by Robert L. Ferris, MD, PhD, and colleagues during the ASCO20 Virtual Scientific Program (Abstract 6500) and in today's Head and Neck Cancer Oral Abstract Session. The trial, conducted in patients undergoing transoral robotic surgery, tested reduced postoperative radiation therapy in patients with human papillom...

Pembrolizumab Increases 24-Month PFS2 in PD-L1+ HNSCC
https://www.targetedonc.com/view/pembrolizumab-increases-24-month-pfs2-in-pd-l1-hnscc

May 29th, 2020 - Patients with PD-L1-positive relapsed/refractory head and neck squamous cell carcinoma (HNSCC) who were treated in the KEYNOTE-048 trial experienced and improvement in progression-free survival after subsequent therapy (PFS2) with pembrolizumab (Keytruda) compared with the EXTREME regimen. The PFS2 benefit was consistent in patients who received pembrolizumab alone and those who received added ...

Key Efficacy End Points Upheld at 3 Years for Cemiplimab in CSCC
https://www.targetedonc.com/view/key-efficacy-end-points-upheld-at-3-years-for-cemiplimab-in-cscc

May 30th, 2020 - Three-year follow-up data from the phase 2 EMPOWER-CSCC-1 trial (NCT02760498) demonstrated a clinically meaningful survival and duration of response (DOR) improvement with cemiplimab-rwlc (Libtayo) in patients with advanced cutaneous squamous cell carcinoma (CSCC).

Longer Follow-Up for Cemiplimab Confirms Superior Efficacy Over Other Regimens for CSCC
https://www.onclive.com/conference-coverage/asco-2020/longer-followup-for-cemiplimab-confirms-superior-efficacy-over-other-regimens-for-cscc

May 30th, 2020 - In the phase 2 trial EMPOWER-CSCC-1 (NCT02760498), up to 3 years of follow-up showed continued response rates, and a clinically meaningful survival and duration of response (DOR) for cemiplimab-rwlc (Libtayo) in patients with advanced cutaneous squamous cell carcinoma (CSCC).

Pembrolizumab Doubles 24-Month PFS2 in PD-L1 HNSCC
https://www.onclive.com/conference-coverage/asco-2020/pembrolizumab-doubles-24month-pfs2-in-pdl1-hnscc

May 29th, 2020 - Treatment with pembrolizumab (Keytruda) improved progression-free survival after subsequent therapy (PFS2) for patients with PD-L1–positive, relapsed/refractory head and neck squamous cell carcinoma (HNSCC) compared with the EXTREME regimen, according to an analysis of the KEYNOTE-048 trial. Pembrolizumab induced better PFS2 outcomes both alone and in combination with chemotherapy.

Patients With HNSCC Experience Longer PFS After Combination Pembrolizumab and Chemotherapy, Subsequent Therapy
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200208/full/

May 29th, 2020 - Patients treated with pembrolizumab or pembrolizumab plus chemotherapy as first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) had longer progression-free survival (PFS) after the next line of therapy than patients first treated with the EXTREME regimen, according to a study presented during the ASCO20 Virtual Scientific Program (Abstract 6505).

Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version (NIH)
https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq
NIH

NSCLC is any type of epithelial lung cancer other than small cell lung cancer (SCLC). The most common types of NSCLC are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma, but there are several other types that occur less frequently, and all types can occur in unusual histologic variants.

FDA approves nivolumab for esophageal squamous cell carcinoma
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-nivolumab-esophageal-squamous-cell-carcinoma
FDA

Jun 9th, 2020 - On June 10, 2020, the Food and Drug Administration approved nivolumab (OPDIVO, Bristol-Myers Squibb Co.) for patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.

Vaginal Cancer Treatment (PDQ®)–Health Professional Version
https://www.cancer.gov/types/vaginal/hp/vaginal-treatment-pdq?cid=eb_govdel
National Cancer Institute

Carcinomas of the vagina are uncommon tumors comprising about 2% of the cancers that arise in the female genital system.[1] Squamous cell carcinoma (SCC) accounts for approximately 80% to 90% of vaginal cancer cases and adenocarcinoma accounts for 5% to 10% of vaginal cancer cases.[1]

Esophageal Cancer Prevention (PDQ®)–Health Professional Version
https://www.cancer.gov/types/esophageal/hp/esophageal-prevention-pdq?cid=eb_govdel
National Cancer Institute

Smoking and drinking alcohol may account for roughly 90% of esophageal squamous cell carcinoma cases in Western countries like the United States.[1] Gastroesophageal reflux/Barrett esophagus is associated with an increased risk of esophageal adenocarcinoma.

Von Hippel-Lindau Disease (PDQ®)–Health Professional Version
https://www.cancer.gov/types/kidney/hp/renal-cell-carcinoma-genetics/vhl-syndrome?cid=eb_govdel
National Cancer Institute

Von Hippel-Lindau disease (VHL) is an autosomal dominant disease with a predisposition to multiple neoplasms. Germline pathogenic variants in the VHL gene predispose individuals to specific types of both benign and malignant tumors and cysts in many organ systems.

Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for PIK3CA-altered head and neck cancer
http://jem.rupress.org/content/early/2019/01/25/jem.20181936?PR=
Hedberg,M.,et al

Jan 24th, 2019 - PIK3CA is the most commonly altered oncogene in head and neck squamous cell carcinoma (HNSCC). We evaluated the impact of nonsteroidal anti-inflammatory drugs (NSAIDs) on survival in a PIK3CA-characterized cohort of 266 HNSCC patients and explored the mechanism in relevant preclinical models including patient-derived xenografts. Among subjects with PIK3CA mutations or amplification, regular NSA...

FDA grants priority review to Keytruda for first-line treatment of advanced head and neck cancer
https://www.healio.com/hematology-oncology/head-neck-cancer/news/online/%7Bf7be7f0c-f55a-4770-89bf-caf27f834e43%7D/fda-grants-priority-review-to-keytruda-for-first-line-treatment-of-advanced-head-and-neck-cancer

Feb 10th, 2019 - The FDA granted priority review to pembrolizumab for first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma. The designation applies to use of pembrolizumab (Keytruda, Merck) — an anti-PD-1 agent — as monotherapy or in combination with platinum and 5-FU chemotherapy.

Association of Vitamin A Intake With Cutaneous Squamous Cell Carcinoma Risk in the United States
https://jamanetwork.com/journals/jamadermatology/fullarticle/2739070
JAMA Dermatology; Kim,J.,et al

Jul 30th, 2019 - Question Is vitamin A intake associated with reduced cutaneous squamous cell carcinoma risk? Findings In this cohort study of 48 400 US men and 75 170 US women, during a follow-up period of more than 26 years, higher total vitamin A intake was associated with a reduction in cutaneous squamous cell carcinoma risk. Meaning This study found an inverse association between intake of vitamin A a...

Osteosarcoma and Malignant Fibrous Histiocytoma of Bone Treatment (PDQ®)–Health Professional Version
https://www.cancer.gov/types/bone/hp/osteosarcoma-treatment-pdq?cid=eb_govdel

Aug 21st, 2019 - Osteosarcoma and malignant fibrous histiocytoma (MFH) of bone treatment depends on site, extent of disease, and grade. Treatment options include surgery, chemotherapy, radiation therapy, and targeted therapy. Get detailed treatment information for osteosarcoma and MFH in this summary for clinicians

FDA approves pembrolizumab for advanced esophageal squamous cell cancer
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-advanced-esophageal-squamous-cell-cancer

Jul 30th, 2019 - On July 30, 2019, the Food and Drug Administration approved pembrolizumab (KEYTRUDA, Merck) for patients with recurrent, locally advanced or metastatic, squamous cell carcinoma of the esophagus (ESCC) whose tumors express PD-L1 (Combined Positive Score [CPS] ≥10), as determined by an FDA-approved test, with disease progression after one or more prior lines of systemic therapy.

FDA Approves New Monotherapy Indication for Merck’s KEYTRUDA® (pembrolizumab)
https://www.mrknewsroom.com/news-release/prescription-medicine-news/fda-approves-new-monotherapy-indication-mercks-keytruda-pemb

Jul 30th, 2019 - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 (Combined Positive Score [CPS] ≥10) as determined by ...

FDA Approves Daiichi Sankyo’s TURALIO™ (pexidartinib) for the Treatment of Select Patients with TGCT, a Rare and Debilitating Tumor
https://dsi.com/press-releases/-/article/364091/10481984

Aug 1st, 2019 - TURALIO is the first and only approved therapy for adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery

Head and neck squamous cell carcinoma
https://ghr.nlm.nih.gov/condition/head-and-neck-squamous-cell-carcinoma

Jul 15th, 2019 - Squamous cell carcinoma is a cancer that arises from particular cells called squamous cells. Squamous cells are found in the outer layer of skin and in the mucous membranes, which are the moist tissues that line body cavities such as the airways and intestines. Head and neck squamous cell carcinoma (HNSCC) develops in the mucous membranes of the mouth, nose, and throat.